About 30 results found for searched term "LAP" (0.021 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1664 | AZD2281 (Olaparib) | PARP |
| Olaparib; KU-0059436 | ||
| AZD 2281 (Olaparib, KU-0059436) is a potent PARP (poly ADP-ribose polymerase) inhibitorwith IC50 of 5 and 1 nM for PARP-1and PARP-2 respectively. Olaparib is an autophagy and mitophagy activator. | ||
| M1802 | Lapatinib ditosylate monohydrate | EGFR/HER2 |
| GW572016 ditosylate monohydrate; GW2016 | ||
| Lapatinib (GW572016) ditosylate monohydrate is a selective and effective inhibitor of EGFR kinase (Ki = 3 nM), ErbB-2 kinase (Ki = 13 nM) and ErbB-4 kinase (Ki = 347 nM). | ||
| M1808 | Telaprevir | HCV Protease |
| VX-950 | ||
| Telaprevir (VX-950) is a novel hepatitis C virus (HCV) NS3-4A protease inhibitor with IC50 of < 0.2 μM. | ||
| M2453 | β-Lapachone | Topoisomerase |
| ARQ-501; NSC-26326 | ||
| β-Lapachone is a selective DNA topoisomerase I inhibitor, exhibiting no inhibitory activities against DNA topoisomerase II or ligase. | ||
| M2733 | GSK2190915 | Lipoxygenase |
| AM-803, Fiboflapon | ||
| GSK2190915 (AM803), a potent FLAP inhibitor, prevents the synthesis of leukotrienes and 5-oxo-ETE, with IC50 of 76 nM for inhibition of LTB4 in human blood, provides treatment for asthma. | ||
| M3426 | Enalaprilat Dihydrate | ACE |
| MK-422 | ||
| Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM. | ||
| M3517 | Lapatinib | EGFR/HER2 |
| GW-572016; GW2016 | ||
| Lapatinib (GW572016) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. | ||
| M3543 | Enalapril Maleate | ACE |
| MK-421 Maleate | ||
| Enalapril Maleate, the active metabolite of enalapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. | ||
| M5285 | Ilaprazole | Proton Pump |
| IY-81149 | ||
| Ilaprazole, a substituted benzimidazole, is a new candidate drug that is an H+ /K+ ATPase inhibitor designed for the treatment of gastric ulcers. | ||
| M5855 | Rilapladib | Phospholipase |
| SB 659032 | ||
| Rilapladib (SB 659032) is a selective Lp-PLA2 (lipoprotein-associated phospholipase A2) inhibitor with an IC50 of 230 pM. Rilapladib (SB 659032) is also a PAFR (Platelet Activating Factor Receptor) antagonist. | ||
| M6892 | LAP | Others |
| LAP (Lithium phenyl-2,4,6-trimethylbenzoylphosphinate) is a water soluble, cytocompatible, Type I photoinitiator for use in the polymerization of hydrogels or other polymeric materials. This photoinitator is preferred over Irgacure 2959 for biological applications due to its increased water solubility, increased polymerization rates with 365 nm light, and absorbance at 400 nm allowing for polymerization with visible light. | ||
| M8580 | Perlapine | Others |
| Perlapine is a potent and selective agonist of hM3Dq DREADD (Designer Receptors Exclusively Activated by Designer Drugs), which does not activate the native human M3 receptor. | ||
| M8809 | Trandolapril | Others |
| RU44570 | ||
| Studies have reported that trandolapril inhibits atherosclerosis1 and decreases the occurrence of atrial fibrillation2. | ||
| M9019 | Rolapitant | Neurokinin Receptor |
| SCH 619734 | ||
| Rolapitant (SCH619734) is an orally bioavailable, centrally-acting, selective neurokinin 1 receptor (NK1-receptor) antagonist with a Ki of 0.66 nM. | ||
| M14087 | Diflapolin | Epoxide Hydrolase |
| Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. | ||
| M14137 | Lapatinib ditosylate | EGFR/HER2 |
| GW572016 ditosylate; GW2016 ditosylate | ||
| Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively. | ||
| M14779 | Talaporfin sodium | Others |
| ME2906; Mono-L-aspartyl chlorin e6; NPe6 | ||
| Talaporfin (ME2906; NPe6) is a photosensitizer used in photodynamic therapy (PDT). | ||
| M15061 | Atuliflapon | Lipoxygenase |
| AZD5718 | ||
| Atuliflapon (AZD5718) is a 5-lox activating protein (FLAP, 5‑Lipoxygenase activating protein) inhibitor that attenuates the 5-lipoxygenase pathway and reduces pro-inflammatory and vasoactive leukotriene (LT) production at an in vitro maximum 50% inhibitory concentration (IC50) of 39nM. | ||
| M16003 | Lappaconitine hydrobromide | Alkaloids |
| Lappaconitine hydrobromide | ||
| M16022 | N-Methylatalaphylline | Alkaloids |
| N-Methylatalaphylline | ||
| M16110 | Atalaphylline | Alkaloids |
| Atalaphylline | ||
| M16556 | 7,4'-Di-O-methylapigenin 5-O-xylosylglucoside | Flavonoids |
| 7,4'-Di-O-methylapigenin 5-O-xylosylglucoside | ||
| M16626 | 7,4'-Di-O-methylapigenin | Flavonoids |
| 7,4'-Di-O-methylapigenin | ||
| M16655 | 8,3'-Diprenylapigenin | Flavonoids |
| 8,3'-Diprenylapigenin | ||
| M16693 | 6-Prenylapigenin | Flavonoids |
| 6-Prenylapigenin | ||
| M17428 | 4,9-Dihydroxy-α-lapachone | Quinones |
| 4,9-Dihydroxy-α-lapachone | ||
| M17433 | α-Lapachone | Quinones |
| α-Lapachone | ||
| M17443 | Lapachol | DHODH |
| Lapachol is a naturally occurring naphthoquinone and orally active, potent inhibitor of dihydroorotic acid dehydrogenase (DHODH).Lapachol has immunosuppressive activity against lymphocytes by inhibiting pyrimidine synthesis through direct blockade of DHODH activity. In addition, Lapachol is a vitamin K antagonist with antitumor and antileishmanial activity that inhibits DNA and RNA synthesis in tumor cells. | ||
| M18089 | Olaparib intermediate 763114-26-7 | Others |
| Olaparib intermediate 763114-26-7 | ||
| M18880 | Lappaconitine | Others |
| Lappaconitine | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
